The use of antiplatelet and/or anticoagulant medications has increased due to irregular diets, limited physical activity, and ...

Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine VERO BEACH, Fla., Dec. 17, 2025 ...

Anthony Uyah has been appointed as the new Managing Director and Chief Operating Officer of M4STV, bringing extensive engineering and leadership experience to enhance the platform’s operations and ...

Investing.com -- Immuneering Corporation (NASDAQ:IMRX) stock gained 2.4% in after-hours trading Wednesday following the company’s announcement that it has completed End-of-Phase 2 interactions with ...

Adding romosozumab to ongoing denosumab treatment shows increased lumbar spine bone mineral density with preserved anabolic ...